Stock listing

BIVA:AGIO Agios Pharmaceuticals, Inc. Acciones

Mexican listing (BIVA) of Agios Pharmaceuticals, Inc. · home listing NASDAQ:AGIO

Follow Agios Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:AGIO

$27.60 USD -2.08 (-7.0%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:AGIO

Past year +12.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$27.43 – $29.14 USDNov 20, 2026
Volume
776,163 sharesNov 20, 2026
Market cap
$1.65B USDAt the close on Nov 20, 2026 · price × 59.81M shares outstanding
52-week range
$23.00 – $44.09 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$34.26M USDMedian day 884,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Agios Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:AGIO · Home$27.60 USD-2.08 (-7.0%)776,163$28.01$29.14$27.43$29.68Close on Nov 20, 2026
LSE:0HB0$28.35 USD-1.598 (-5.3%)63$27.56$28.47$27.56$29.95Close on Nov 20, 2026
Frankfurt:8AP€25.60 EUR-1.60 (-5.9%)—€25.60€25.60€25.60€27.20Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AGIO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$27.60-2.08-7.0%$28.01$29.14$27.43776,163
$29.68-0.21-0.7%$29.57$30.48$29.22600,081
$29.89-0.26-0.9%$30.13$30.38$28.95630,571
$30.15-1.44-4.6%$31.29$31.70$30.10540,853
$31.59-0.17-0.5%$31.64$31.97$30.81371,333
$31.76-1.06-3.2%$32.56$32.63$31.56497,036
$32.82+1.06+3.3%$31.75$33.12$31.56844,598
$31.76+0.38+1.2%$31.00$31.89$30.481,005,362
$31.38+1.97+6.7%$29.32$31.45$28.931,341,934
$29.41+1.14+4.0%$28.99$29.79$28.471,280,124
$28.27-3.11-9.9%$31.19$31.19$27.572,551,342
$31.38+0.18+0.6%$32.09$32.09$30.56917,639
$31.20+1.25+4.2%$30.20$31.63$30.06684,855
$29.95-0.60-2.0%$30.95$31.41$29.831,912,494
$30.55-6.68-17.9%$31.43$33.00$29.803,094,260
$37.23-0.89-2.3%$38.23$38.49$36.79851,005
$38.12+0.09+0.2%$37.46$38.44$36.861,201,320
$38.03+1.18+3.2%$36.59$38.07$36.30738,982
$36.85-0.15-0.4%$37.32$38.13$36.63838,530
$37.00-0.19-0.5%$36.93$37.32$36.10920,047
$37.19+0.010.0%$37.22$37.74$36.35931,100
$37.18+0.54+1.5%$36.62$37.59$36.46849,792
$36.64+1.74+5.0%$35.06$37.00$35.021,518,758
$34.90+3.58+11.4%$31.61$35.03$31.611,972,930
$31.32-1.00-3.1%$32.35$32.52$31.16952,684
$32.32+1.35+4.4%$31.70$32.84$31.352,048,391
$30.97+0.76+2.5%$30.07$31.11$29.67930,895
$30.21-0.61-2.0%$30.60$30.99$30.101,168,600
$30.82-0.99-3.1%$31.84$32.22$30.69647,800
$31.81-0.11-0.3%$31.85$32.15$31.52835,700
$31.92+0.13+0.4%$31.46$32.32$31.162,078,600
$31.79+0.07+0.2%$31.37$32.27$31.071,673,100
$31.72+0.47+1.5%$31.49$32.03$30.791,278,300
$31.25-0.55-1.7%$31.65$31.76$30.78808,700
$31.80-0.68-2.1%$32.82$32.82$31.65569,900
$32.48-0.77-2.3%$33.25$33.73$32.421,703,700
$33.25-0.05-0.2%$33.67$34.06$33.201,548,500
$33.30-0.12-0.4%$33.21$33.55$32.70416,400
$33.42+0.84+2.6%$32.53$34.12$32.351,347,700
$32.58-0.32-1.0%$32.93$33.33$32.54996,500
$32.90-1.29-3.8%$34.02$34.13$31.371,635,100
$34.19-0.78-2.2%$34.85$35.09$34.09752,500
$34.97+1.02+3.0%$34.19$35.36$33.881,170,400
$33.95+0.88+2.7%$33.70$34.14$33.30884,500
$33.07-0.54-1.6%$33.29$33.40$32.771,566,200
$33.61+0.66+2.0%$33.42$34.30$33.19956,700
$32.95+0.14+0.4%$32.89$33.75$32.74863,500
$32.81-0.41-1.2%$33.23$33.48$32.221,354,000
$33.22-0.38-1.1%$33.83$34.36$32.89794,500
$33.60-0.04-0.1%$33.94$34.28$33.32750,200
$33.64-0.99-2.9%$34.26$35.28$33.21720,200
$34.63+1.08+3.2%$33.14$35.38$33.141,024,600
$33.55+0.45+1.4%$32.53$33.93$32.23816,400
$33.10-0.03-0.1%$33.13$33.50$32.92480,200
$33.13-1.00-2.9%$34.28$34.39$32.95516,000
$34.13-0.08-0.2%$34.49$34.93$33.54771,700
$34.21+0.53+1.6%$33.60$34.34$33.21926,800
$33.68+0.36+1.1%$33.09$33.87$32.931,109,600
$33.32-0.96-2.8%$33.94$34.36$33.27519,700
$34.28+0.29+0.9%$33.94$34.81$33.611,001,400
$33.99+0.09+0.3%$33.84$34.43$33.24812,000
$33.90+1.26+3.9%$32.85$34.26$32.84742,188
$32.64-0.45-1.4%$33.25$33.25$32.61635,734
$33.09-0.54-1.6%$33.62$34.09$32.95577,600
$33.63-1.49-4.2%$34.64$35.09$33.61697,500
Ticker
BIVA:AGIO
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
BIVA
Currency
MXN

What changed lately

Latest news

All Agios Pharmaceuticals, Inc. news

Agios Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
25 in the last 12 months · 221 in all · newest Nov 5, 2026 · oldest 2019
Calls
27 calls with a replay · 27 with a transcript · latest Nov 5, 2026
Decks
38 decks · latest Jul 30, 2026

Where Agios Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:AGIO · Home listingNASDAQUnited StatesUSD
Lang & Schwarz:A1W2RMLang & SchwarzGermanyEUR
LS Exchange:A1W2RMLS ExchangeGermanyEUR
gettex:8APgettexGermanyEUR
LSE:0HB0LSEUnited KingdomUSD
BMV:AGIOBMVMexicoMXN
Tradegate:8APTradegateGermanyEUR
BOATS:AGIOBOATSUnited StatesUSD
BIVA:AGIO · This pageBIVAMexicoMXN
BX Swiss:8APBX SwissSwitzerlandCHF
Dusseldorf:8APDusseldorfGermanyEUR
Frankfurt:8APFrankfurtGermanyEUR
Munich:8APMunichGermanyEUR
Stuttgart:8APStuttgartGermanyEUR

Valuation

EV/sales 7.4× against a median of 3.5×: 10th lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.05B USD
P/E
Loss
EV/sales
7.4×
EV/EBITDA
Negative EBITDA
Price/book
1.7×
Gross margin
91.9%
Operating margin
−297.7%
Net margin
−264.8%
Debt to equity
0.0×
Beta vs S&P 500
1.10

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Agios Pharmaceuticals, Inc. · NASDAQ:AGIOUS$1.65BUS$1.05Bn/a7.4×n/a1.7×−264.8%0.0×1.10
Ultragenyx Pharmaceutical Inc. · NASDAQ:RAREUS$1.68BUS$2.60Bn/a3.6×n/an/a−71.8%n/a1.35
Supernus Pharmaceuticals, Inc. · NASDAQ:SUPNUS$1.67BUS$1.85B3.7×1.4×n/an/a32.9%n/a0.67
Caplin Point Laboratories Limited · NSE:CAPLIPOINTUS$1.66BUS$1.56B23.2×6.3×18.1×4.3×29.1%0.0×n/a
AstraZeneca Pharma India Limited · NSE:ASTRAZENUS$1.66BUS$1.60B86.8×5.7×59.3×17.5×6.8%0.0×n/a
Hugel, Inc. · KRX:145020US$1.66BUS$1.21B14.1×3.4×7.1×2.1×32.9%0.0×n/a
Faes Farma, S.A. · BME:FAEUS$1.65BUS$1.93B11.0×1.7×5.8×1.9×13.1%0.5×n/a
Consun Pharmaceutical Group Ltd. · HKEX:1681US$1.64BUS$1.06B10.1×2.1×5.6×2.3×31.6%0.1×n/a
BrightGene Bio-Medical Technology Co. Ltd. Class A · SSE:688166US$1.63BUS$1.68B106×8.3×n/a3.5×7.6%0.5×n/a
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A · SZSE:002399US$1.62BUS$986.2M57.0×1.3×n/a0.9×3.7%0.0×n/a
NATCO Pharma Limited · NSE:NATCOPHARMUS$1.62BUS$1.62B13.1×4.3×14.2×1.6×32.8%0.0×n/a
Median of the othersUS$1.65BUS$1.61B14.1×3.5×10.7×2.2×21.1%0.0×1.01

Forecasts

7 strong buy · 3 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
46.11 USD · Analysts' mean
EPS, year to Dec 2026
-5.56 · 7 analysts
Revenue, year to Dec 2026
185.3M · 9 analysts

Team and board

Officers

OfficerRole
Brian GoffChief Executive Officer
Cecilia JonesChief Financial Officer
Jim BurnsChief Legal Officer
Contacts:Investor ContactMorgan SanfordVice President, Investor Relations Agios
Ellen LoprestiChief People Officer
Krishnan ViswanadhanChief Strategy and Operations Officer
Sarah GheuensChief Medical Officer, Head of R&D
Tsveta MilanovaChief Commercial Officer

Board

DirectorRole
Catherine OwenIndependent Director
Cynthia SmithIndependent Director
David ScaddenIndependent Director
Jackie FouseIndependent Director
Jay BackstromIndependent Director
Jeffrey CapelloIndependent Director
Kaye FosterIndependent Director
Maykin HoIndependent Director
Rahul BallalIndependent Director

Events

Calls

CallWhenStatus
Agios Pharmaceuticals (NASDAQ:AGIO) Q3 2026 Earnings CallThu, Nov 05, 2026 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q2 2026 Earnings CallThu, Jul 30, 2026 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q1 2026 Earnings CallWed, Apr 29, 2026 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q4 2025 Earnings CallThu, Feb 12, 2026 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q3 2025 Earnings CallThu, Oct 30, 2025 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q2 2025 Earnings CallThu, Jul 31, 2025 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q1 2025 Earnings CallThu, May 01, 2025 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q4 2024 Earnings CallThu, Feb 13, 2025 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q3 2024 Earnings CallThu, Oct 31, 2024 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q2 2024 Earnings CallThu, Aug 01, 2024 · 8:00 AM ETReplay
All 27 calls
CallWhenStatus
Agios Pharmaceuticals (NASDAQ:AGIO) Q1 2024 Earnings CallThu, May 02, 2024 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q4 2023 Earnings CallThu, Feb 15, 2024 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q3 2023 Earnings CallThu, Nov 02, 2023 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q2 2023 Earnings CallThu, Aug 03, 2023 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q1 2023 Earnings CallThu, May 04, 2023 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q4 2022 Earnings CallThu, Feb 23, 2023 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q3 2022 Earnings CallThu, Nov 03, 2022 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q2 2022 Earnings CallThu, Aug 04, 2022 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q1 2022 Earnings CallThu, May 05, 2022 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q4 2021 Earnings CallThu, Feb 24, 2022 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q3 2021 Earnings CallWed, Nov 03, 2021 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q2 2021 Earnings CallThu, Jul 29, 2021 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q1 2021 Earnings CallThu, Apr 29, 2021 · 8:00 AM ETReplay
Agios Pharmaceuticals (NASDAQ:AGIO) Q4 2020 Earnings CallThu, Feb 25, 2021Replay
Agios Pharmaceuticals (NASDAQ:AGIO) Q3 2020 Earnings CallThu, Nov 05, 2020Replay
Agios Pharmaceuticals (NASDAQ:AGIO) Q2 2020 Earnings CallThu, Jul 30, 2020Replay
Agios Pharmaceuticals (NASDAQ:AGIO) Q1 2020 Earnings CallThu, Apr 30, 2020Replay

Results days

QuarterResultsShare move
Q3 2026Nov 5, 2026 · Before open−9.9%
Q2 2026Jul 30, 2026 · Before open−6.5%
Q1 2026Apr 29, 2026 · Before open+13.1%
Q4 2025Feb 12, 2026+0.9%
Q3 2025Oct 30, 2025 · Before open+2.9%
Q2 2025Jul 31, 2025 · Before open−0.8%
Q1 2025May 1, 2025 · Before open+4.2%
Q4 2024Feb 13, 2025 · Before open+1.5%
Q3 2024Oct 31, 2024 · Before open−4.0%
Q2 2024Aug 1, 2024 · Before open−4.1%
All 20 quarters
QuarterResultsShare move
Q1 2024May 2, 2024 · Before open+2.7%
Q4 2023Feb 15, 2024 · Before open+3.5%
Q3 2023Nov 2, 2023 · Before open−1.4%
Q2 2023Aug 3, 2023 · Before open−0.1%
Q1 2023May 4, 2023 · Before open+7.7%
Q4 2022Feb 23, 2023 · Before open−1.7%
Q3 2022Nov 3, 2022 · Before open−5.3%
Q2 2022Aug 4, 2022 · Before open+14.7%
Q1 2022May 5, 2022 · Before open−4.7%
Q4 2021Feb 24, 2022 · Before open+5.7%

Open Events

Decks

DeckKindSlidesDate
Q2 2026 Earnings PresentationEarnings26 slidesJul 30, 2026
Technical Presentation (June 2026)Technical18 slidesJune 2026
EHA 2026 CongressConference24 slidesJune 2026
Q1 2026 Earnings PresentationEarnings25 slidesApr 29, 2026
Q4 2025 Earnings PresentationEarnings26 slidesFeb 12, 2026
J.P. Morgan Healthcare Conference 2026Conference33 slidesJan 14, 2026
Technical Presentation (November 2025)Technical26 slidesNovember 2025
Q3 2025 Earnings PresentationEarnings28 slidesOct 30, 2025
Q2 2025 Earnings PresentationEarnings27 slidesJul 31, 2025
Q1 2025 Earnings PresentationEarnings38 slidesMay 1, 2025
All 38 decks
DeckKindSlidesDate
Q4 2024 Earnings PresentationEarnings37 slidesFeb 13, 2025
J.P. Morgan Healthcare Conference 2025Conference28 slidesJan 13, 2025
Q3 2024 Earnings PresentationEarnings41 slidesOct 31, 2024
Technical Presentation (September 2024)Technical21 slidesSeptember 2024
Q2 2024 Earnings PresentationEarnings35 slidesAug 1, 2024
Technical Presentation (June 2024)Technical60 slidesJune 2024
Q1 2024 Earnings PresentationEarnings37 slidesMay 2, 2024
Q4 2023 Earnings PresentationEarnings36 slidesFeb 15, 2024
J.P. Morgan Healthcare Conference 2024Conference28 slidesJan 8, 2024
Investor Presentation (January 2024)Investor deck22 slidesJanuary 2024
Q3 2023 Earnings PresentationEarnings26 slidesNov 2, 2023
Q2 2023 Earnings PresentationEarnings31 slidesAug 3, 2023
Q1 2023 Earnings PresentationEarnings24 slidesMay 4, 2023
Investor Presentation (January 2023)Investor deck23 slidesJan 9, 2023
European Haematology Association (EHA) Virtual Congress 2021Conference21 slidesJune 2021
39th Annual J.P. Morgan Healthcare Conference 2021Conference24 slidesJan 12, 2021
Merger or Acquisition (December 2020)Merger or acquisition23 slidesDec 21, 2020
Q3 2020 Earnings PresentationEarnings18 slidesNov 5, 2020
Q2 2020 Earnings PresentationEarnings19 slidesJul 30, 2020
Q1 2020 Earnings PresentationEarnings22 slidesApr 30, 2020
38th Annual J.P. Morgan Healthcare Conference (January 2020)Conference26 slidesJan 13, 2020
2019 ASH Investor ReceptionConference37 slidesDec 9, 2019
Investor Day (May 2018)Investor day152 slidesMay 4, 2018
JPMorgan Healthcare Conference 2017Conference33 slidesJan 9, 2017
JPMorgan Healthcare Conference 2016Conference30 slidesJan 11, 2016
Investor Day (October 2015)Investor day145 slidesOct 16, 2015
Investor Day (October 2014)Investor day130 slidesOct 15, 2014
Investor Presentation (January 2014)Investor deck33 slidesJan 13, 2014

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue54.0M36.5M26.8M14.2M00117.9M94.4M43.0M69.9M
Cost of revenue6.34M4.17M2.88M1.70M001.32M1.40M00
Gross profit42.5M32.3M17.3M12.5M-18.8M-18.8M116.6M93.0M43.0M69.9M
Research and development339.5M301.3M295.5M279.9M257.0M220.8M214.3M341.3M292.7M220.2M
Selling, general and administrative180.3M156.8M119.9M121.7M121.4M115.1M102.0M114.1M71.1M50.7M
Operating income-472.1M-425.7M-391.5M-389.0M-378.4M-335.9M-316.3M-362.5M-320.8M-201.0M
Depreciation and amortization5.20M5.70M6.60M8.40M8.80M9.40M8.09M7.17M6.43M5.71M
EBITDA-466.9M-420.0M-384.9M-380.6M-369.6M-326.5M-308.2M-355.3M-314.4M-195.3M
Interest expense12.8M836.0K17.8M14.9M16.5M6.12M2.51M
Income before tax-413.8M718.0M-352.1M-231.8M-356.5M-329.3M-301.4M-346.0M-314.7M-198.5M
Income tax-1.02M44.2M00-1.98B7.85M0000
Net income-412.8M673.7M-352.1M-231.8M1.60B-327.4M-411.5M-346.0M-314.7M-198.5M
Earnings per share, basic-7.1211.86-6.33-4.2326.55-4.74-6.86-6.03-6.75-5.07
Earnings per share, diluted-7.1211.64-6.33-4.2326.55-4.74-6.86-6.03-6.75-5.07

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents89.1M76.2M88.2M139.3M203.1M127.4M80.9M70.5M102.7M160.8M
Short-term investments765.3M817.5M688.7M643.9M816.9M445.5M483.9M514.8M321.2M380.6M
Receivables10.6M4.11M2.81M2.21M4.38M25.4M15.3M10.4M3.84M8.31M
Inventory32.9M27.6M19.1M8.49M014.7M7.33M869.0K0-32.3M
Current assets942.1M965.6M833.8M832.8M1.06B636.7M611.7M613.8M445.3M559.9M
Property, plant and equipment10.8M11.7M15.4M23.0M28.9M30.8M31.5M24.3M24.4M25.3M
Goodwill00
Total assets1.30B1.66B937.1M1.24B1.44B853.0M890.7M858.5M614.4M619.1M
Accounts payable18.4M16.6M9.78M18.6M16.7M17.7M21.9M17.9M22.8M17.1M
Current liabilities82.2M81.2M68.0M62.6M59.8M94.4M92.9M93.5M94.9M88.4M
Long-term debt00
Total debt40.2M57.0M72.0M85.7M97.1M105.2M113.7M
Total liabilities104.1M122.2M126.1M137.9M145.8M453.5M250.2M170.9M238.9M260.5M
Shareholders' equity1.19B1.54B811.0M1.10B1.29B399.5M640.5M687.5M375.5M358.6M
Shares outstanding58.4M57.2M55.9M55.0M54.3M69.3M68.4M58.2M48.8M42.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-373.0M-389.8M-296.1M-309.5M-407.3M-290.8M-370.6M-304.4M-285.2M38.6M
Capital spending-4.32M-1.69M-999.0K-4.88M-5.74M-14.1M-12.0M-6.99M-4.63M-9.91M
Free cash flow-377.3M-391.5M-297.1M-314.4M-413.1M-304.9M-382.6M-311.4M-289.9M28.6M
Cash from investing377.2M363.4M239.6M243.3M1.25B75.7M91.4M-273.8M-57.9M-119.3M
Cash from financing8.68M14.4M5.43M2.35M-765.8M261.5M289.6M546.0M285.1M169.8M
Dividends paid-37.3M00
Share buybacks02.68M-802.5M11.3M289.7M546.0M285.1M169.8M
Change in cash12.9M-12.0M-51.1M-63.9M75.7M46.5M10.4M-32.2M-58.0M89.0M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
4 · Change in ownershipOct 28, 2026Insider tradeSEC
144 · Notice of proposed saleOct 26, 2026Other filingsSEC
4 · Change in ownershipOct 23, 2026Insider tradeSEC
144 · Notice of proposed saleOct 22, 2026Other filingsSEC
144 · Notice of proposed saleOct 21, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipAug 6, 2026Insider tradeSEC
144 · Notice of proposed saleAug 4, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 3, 2026Big-stake noticeSEC
10-Q · Quarterly reportJul 30, 2026Quarterly reportSEC
8-K · Current reportJul 30, 2026ResultsSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJul 2, 2026Big-stake noticeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
S-8 · Registration statement for employee plansJun 18, 2026Offer documentSEC
8-K · Current reportJun 18, 2026Management or board changeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 6, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 29, 2026Big-stake noticeSEC
10-Q · Quarterly reportApr 29, 2026Quarterly reportSEC
8-K · Current reportApr 29, 2026ResultsSEC
ARS · Annual report to shareholdersApr 24, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2026Meeting noticeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
144 · Notice of proposed saleApr 2, 2026Other filingsSEC
144 · Notice of proposed saleApr 2, 2026Other filingsSEC
144 · Notice of proposed saleApr 2, 2026Other filingsSEC
144 · Notice of proposed saleApr 2, 2026Other filingsSEC
144 · Notice of proposed saleApr 2, 2026Other filingsSEC
144 · Notice of proposed saleApr 2, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
S-3ASR · Registration statementFeb 12, 2026Offer documentSEC
10-K · Annual reportFeb 12, 2026Annual reportSEC
8-K · Current reportFeb 12, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 9, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 9, 2026Big-stake noticeSEC
8-K · Current reportJan 12, 2026Current reportSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
144 · Notice of proposed saleJan 5, 2026Other filingsSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
144 · Notice of proposed saleDec 30, 2025Other filingsSEC
144 · Notice of proposed saleDec 30, 2025Other filingsSEC
144 · Notice of proposed saleDec 30, 2025Other filingsSEC
144 · Notice of proposed saleDec 30, 2025Other filingsSEC
144 · Notice of proposed saleDec 30, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 5, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
144 · Notice of proposed saleNov 12, 2025Other filingsSEC
4 · Change in ownershipNov 3, 2025Insider tradeSEC
144 · Notice of proposed saleOct 30, 2025Other filingsSEC
10-Q · Quarterly reportOct 30, 2025Quarterly reportSEC
8-K · Current reportOct 30, 2025ResultsSEC
4 · Change in ownershipOct 29, 2025Insider tradeSEC
144 · Notice of proposed saleOct 27, 2025Other filingsSEC
4 · Change in ownershipOct 10, 2025Insider tradeSEC
144 · Notice of proposed saleOct 8, 2025Other filingsSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipSep 30, 2025Insider tradeSEC
144 · Notice of proposed saleSep 30, 2025Other filingsSEC
144 · Notice of proposed saleSep 26, 2025Other filingsSEC
4 · Change in ownershipSep 9, 2025Insider tradeSEC
4 · Change in ownershipAug 29, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeAug 28, 2025Big-stake noticeSEC
144 · Notice of proposed saleAug 27, 2025Other filingsSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
4 · Change in ownershipAug 12, 2025Insider tradeSEC
144 · Notice of proposed saleAug 8, 2025Other filingsSEC
8-K · Current reportAug 4, 2025Current reportSEC
10-Q · Quarterly reportJul 31, 2025Quarterly reportSEC
8-K · Current reportJul 31, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 17, 2025Big-stake noticeSEC
4 · Change in ownershipJul 15, 2025Insider tradeSEC
4 · Change in ownershipJul 11, 2025Insider tradeSEC
144 · Notice of proposed saleJul 10, 2025Other filingsSEC
4 · Change in ownershipJul 10, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 10, 2025Insider tradeSEC
144 · Notice of proposed saleJul 9, 2025Other filingsSEC
8-K · Current reportJul 8, 2025Management or board changeSEC
SCHEDULE 13G · Big-stake noticeJul 7, 2025Big-stake noticeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
144 · Notice of proposed saleJul 1, 2025Other filingsSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
144 · Notice of proposed saleJun 24, 2025Other filingsSEC
144 · Notice of proposed saleJun 24, 2025Other filingsSEC
144 · Notice of proposed saleJun 24, 2025Other filingsSEC
144 · Notice of proposed saleJun 24, 2025Other filingsSEC
144 · Notice of proposed saleJun 24, 2025Other filingsSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
S-8 · Registration statement for employee plansJun 18, 2025Offer documentSEC
8-K · Current reportJun 18, 2025Management or board changeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 1, 2025Quarterly reportSEC
8-K · Current reportMay 1, 2025ResultsSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
4 · Change in ownershipApr 10, 2025Insider tradeSEC
144 · Notice of proposed saleApr 8, 2025Other filingsSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 7, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMar 5, 2025Offer documentSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
144 · Notice of proposed saleMar 3, 2025Other filingsSEC
144 · Notice of proposed saleMar 3, 2025Other filingsSEC
144 · Notice of proposed saleMar 3, 2025Other filingsSEC
144 · Notice of proposed saleMar 3, 2025Other filingsSEC
144 · Notice of proposed saleMar 3, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
10-K · Annual reportFeb 13, 2025Annual reportSEC
8-K · Current reportFeb 13, 2025ResultsSEC
8-K · Current reportFeb 13, 2025Management or board changeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 4, 2025Big-stake noticeSEC
8-K · Current reportJan 13, 2025Current reportSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
8-K · Current reportJan 6, 2025Current reportSEC
144 · Notice of proposed saleJan 3, 2025Other filingsSEC
4 · Change in ownershipDec 13, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
4 · Change in ownershipNov 13, 2024Insider tradeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
144 · Notice of proposed saleNov 8, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedNov 8, 2024Big-stake noticeSEC
144 · Notice of proposed saleNov 7, 2024Other filingsSEC
144 · Notice of proposed saleNov 7, 2024Other filingsSEC
10-Q · Quarterly reportOct 31, 2024Quarterly reportSEC
8-K · Current reportOct 31, 2024ResultsSEC
4 · Change in ownershipSep 30, 2024Insider tradeSEC
4 · Change in ownershipAug 13, 2024Insider tradeSEC
4 · Change in ownershipAug 13, 2024Insider tradeSEC

This page holds 200 of 1,001 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Agios Pharmaceuticals, Inc.’s releases · as of Oct 30, 2026

Common shares
59,809,651
Fully diluted
59,809,651

Fully diluted

LineSharesAs of
Common shares59,809,651Oct 30, 2026

Share count over time

CountShares
Oct 30, 202659,809,651

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
BlackRock6.23MUS$207MSep 30, 2026
Vanguard6.03MUS$201MSep 30, 2026
Farallon Capital Management, L.L.C.5.94MUS$197MSep 30, 2026
D. E. Shaw & Co., Inc.3.89MUS$129MSep 30, 2026
Morgan Stanley3.44MUS$114MSep 30, 2026
State Street3.26MUS$109MSep 30, 2026
Armistice Capital, LLC2.58MUS$85.7MSep 30, 2026
Nomura1.96MUS$65.1MSep 30, 2026
Assenagon Asset Management S.A.1.89MUS$62.7MSep 30, 2026
Erste Asset Management GmbH1.8MUS$60.1MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Geode Capital1.58MUS$52.6MSep 30, 2026
BNP Paribas1.55MUS$51.5MSep 30, 2026
GW&K Investment Management, LLC1.4MUS$46.4MSep 30, 2026
Susquehanna1.32MUS$43.9MSep 30, 2026
Dimensional1.29MUS$42.8MSep 30, 2026
Goldman Sachs1.15MUS$38.1MSep 30, 2026
ADAR1 Capital Management, LLC1.14MUS$37.9MSep 30, 2026
UBS1.05MUS$34.9MSep 30, 2026
Two Sigma906KUS$30.1MSep 30, 2026
Foresite Capital Management VI LLC827KUS$27.5MSep 30, 2026
Citadel779KUS$25.9MSep 30, 2026
AQR Capital Management LLC747KUS$24.8MSep 30, 2026
Bank of America715KUS$23.8MSep 30, 2026
Nuveen681KUS$22.6MSep 30, 2026
Parkman Healthcare Partners LLC633KUS$21.1MSep 30, 2026
SCS Capital Management LLC613KUS$20.4MSep 30, 2026
Arrowstreet Capital, Limited Partnership609KUS$20.2MSep 30, 2026
Defilade Capital Management, L.P.570KUS$19MSep 30, 2026
Schwab565KUS$18.8MSep 30, 2026
Qube Research & Technologies Ltd556KUS$18.5MSep 30, 2026
Northern Trust545KUS$18.1MSep 30, 2026
Renaissance Technologies506KUS$16.8MSep 30, 2026
Lynx1 Capital Management LP473KUS$15.7MSep 30, 2026
Rock Springs Capital Management LP472KUS$15.7MSep 30, 2026
Glenview Capital Management, LLC460KUS$15.3MSep 30, 2026
Legal & General419KUS$13.9MSep 30, 2026
Panagora Asset Management Inc409KUS$13.6MSep 30, 2026
Schonfeld Strategic Advisors LLC404KUS$13.4MSep 30, 2026
Jane Street389KUS$12.9MSep 30, 2026
Kennedy Capital Management LLC370KUS$12.3MSep 30, 2026
Jacobs Levy Equity Management, Inc357KUS$11.9MSep 30, 2026
Algert Global LLC312KUS$10.4MSep 30, 2026
Man Group plc280KUS$9.3MSep 30, 2026
Millennium274KUS$9.13MSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.244KUS$8.12MSep 30, 2026
Group One Trading LLC229KUS$7.6MSep 30, 2026
Tetragon Partners GP Ltd216KUS$7.17MSep 30, 2026
First Trust215KUS$7.14MSep 30, 2026
Palo Alto Investors LP201KUS$6.68MSep 30, 2026
BNY199KUS$6.61MSep 30, 2026

This page holds 50 of 236 holders. Open Shareholders

Funds

HolderSharesValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF2.01MUS$74.4MJun 30, 2026
Vanguard Total Stock Market Index Fund1.89MUS$70.1MJun 30, 2026
iShares Russell 2000 ETF1.54MUS$57.1MJun 30, 2026
Vanguard Small-Cap Index Fund1.36MUS$50.6MJun 30, 2026
Nomura Small Cap Core Fund1.14MUS$33.7MMay 29, 2026
Vanguard Small-Cap Growth Index Fund789KUS$29.3MJun 30, 2026
Vanguard Extended Market Index Fund684KUS$25.4MJun 30, 2026
Fidelity Small Cap Index Fund646KUS$19.4MJul 31, 2026
iShares Russell 2000 Value ETF520KUS$19.3MJun 30, 2026
Strategic Advisers U.S. Total Stock Fund482KUS$14.2MMay 31, 2026
Show 50 holders
HolderSharesValueAs of
iShares Biotechnology ETF395KUS$14.7MJun 30, 2026
College Retirement Equities Fund - Total Global Stock Account333KUS$12.3MJun 30, 2026
Nuveen Quant Small Cap Equity Fund308KUS$9.25MJul 31, 2026
Fidelity Extended Market Index Fund304KUS$8.93MMay 31, 2026
Vanguard Russell 2000 Index Fund290KUS$8.53MMay 31, 2026
Schwab U.S. Small-Cap ETF281KUS$8.25MMay 31, 2026
BlackRock Health Sciences Opportunities Portfolio272KUS$7.99MMay 29, 2026
U.S. Small Cap Portfolio258KUS$7.74MJul 31, 2026
U.S. Micro Cap Portfolio245KUS$7.37MJul 31, 2026
BlackRock Advantage Small Cap Core Fund199KUS$5.84MMay 29, 2026
AMG GW&K Small Cap Core Fund193KUS$7.15MJun 30, 2026
Dimensional U.S. Small Cap ETF192KUS$5.78MJul 31, 2026
Vanguard Strategic Equity Fund167KUS$6.22MJun 30, 2026
Vanguard Health Care Index Fund166KUS$4.88MMay 31, 2026
Dimensional U.S. Core Equity 2 ETF148KUS$4.45MJul 31, 2026
Schwab Small-Cap Index Fund144KUS$4.31MJul 31, 2026
First Trust Small Cap Growth AlphaDEX Fund139KUS$4.18MJul 31, 2026
Vanguard Growth And Income Fund120KUS$4.44MJun 30, 2026
Invesco RAFI US 1500 Small-Mid ETF113KUS$3.4MJul 31, 2026
Nuveen Quant Small/Mid Cap Equity Fund110KUS$3.31MJul 31, 2026
Avantis U.S. Small Cap Equity ETF110KUS$3.23MMay 31, 2026
Fidelity Total Market Index Fund109KUS$3.2MMay 31, 2026
Master Small Cap Index Series107KUS$3.99MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.93,727US$3.48MJun 30, 2026
Fidelity Series Total Market Index Fund89,223US$2.62MMay 31, 2026
JPMorgan U.S. Small Company Fund87,033US$3.23MJun 30, 2026
Meridian Growth Fund84,010US$3.12MJun 30, 2026
U.S. Core Equity 2 Portfolio81,402US$2.44MJul 31, 2026
Nuveen Small Cap Blend Index Fund78,384US$2.35MJul 31, 2026
Fidelity Small Cap Value Index Fund77,838US$2.89MJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF76,190US$2.83MJun 30, 2026
North Square Dynamic Small Cap Fund74,184US$2.18MMay 31, 2026
AMG GW&K Small Cap Value Fund72,620US$2.69MJun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares67,945US$2.04MJul 31, 2026
EQ/2000 Managed Volatility Portfolio64,214US$2.38MJun 30, 2026
U.S. Core Equity 1 Portfolio63,575US$1.91MJul 31, 2026
ALPS Medical Breakthroughs ETF60,392US$1.78MMay 31, 2026
JPMorgan Small Cap Value Fund58,798US$2.18MJun 30, 2026
First Trust Small Cap Core AlphaDEX Fund47,013US$1.41MJul 31, 2026
Vanguard Total World Stock Index Fund46,943US$1.41MJul 31, 2026

This page holds 50 of 226 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Gheuens Sarah
Officer: Chief Medical Officer
Sale7,866USD 37.69US$296KOct 26, 2026
Gheuens Sarah
Officer: Chief Medical Officer
Sale500USD 37.52US$18,760Oct 22, 2026
Gheuens Sarah
Officer: Chief Medical Officer
Sale1,489USD 37.53US$55,882Oct 21, 2026
Gheuens Sarah
Officer: Chief Medical Officer
Sale30,000USD 30.48US$914KAug 4, 2026
Gheuens Sarah
Officer: Chief Medical Officer
Sale4,007USD 37.56US$151KJul 1, 2026
Goff Brian
Director, Officer: Chief Executive Officer
Sale12,472USD 34.71US$433KApr 2, 2026
Goff Brian
Director, Officer: Chief Executive Officer
Sale6,596USD 34.71US$229KApr 2, 2026
Viswanadhan Krishnan
Officer: Chief Corp Dev & Strategy
Sale2,959USD 34.71US$103KApr 2, 2026
Milanova Tsveta
Officer: Chief Commercial Officer
Sale3,262USD 34.71US$113KApr 2, 2026
Jones Cecilia
Officer: Chief Financial Officer
Sale3,141USD 34.71US$109KApr 2, 2026
All 12 trades
TradeTradeSharesPriceValueDate
Gheuens Sarah
Officer: Chief Medical Officer
Sale2,940USD 34.71US$102KApr 2, 2026
Burns James William
Officer: Chief Legal Officer
Sale3,280USD 34.71US$114KApr 2, 2026

Big stakes

StakeStakeSharesDateFiling
Farallon Capital Management, L.L.C.9.90%5.92MJun 30, 2026Schedule 13G
BlackRock, Inc.7.80%4.51MJun 30, 2025Schedule 13G
D. E. Shaw & Co., L.P.6.50%3.89MSep 30, 2026Schedule 13G
Morgan Stanley5.70%3.43MSep 30, 2026Schedule 13G
State Street Corp5.30%3.11MDec 31, 2025Schedule 13G
Vanguard Capital Management LLC5.27%3.09MMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Robert Nelsen
Other companies: City Therapeutics, Inc. (Board Director · Since at least Oct 19, 2026); Kardigan, Inc. (Director · Since at least Jun 22, 2026); Metsera, Inc. (Director · Since at least Nov 13, 2025); Prime Medicine, Inc. (Board Member · Since at least Oct 19, 2022); Sana Biotechnology, Inc. (Director · Since at least Feb 3, 2021); Lyell Immunopharma, Inc. (Director · Jun 16, 2021 – Jun 14, 2024 · Past); Revolution Healthcare Acquisition Corp (Director · Mar 17, 2021 – Mar 17, 2021 · Past); Beam Therapeutics Inc. (Director · Feb 5, 2020 – Mar 31, 2021 · Past); Vir Biotechnology, Inc. (Director · Oct 10, 2019 – May 30, 2024 · Past); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Apr 13, 2021 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 18, 2020 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jun 2, 2021 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Jun 8, 2017 · Past); Bellerophon Therapeutics Inc (Director · Feb 12, 2015 – Feb 13, 2015 · Past); Juno Therapeutics Inc (Director · Dec 18, 2014 – Mar 5, 2018 · Past); Sage Therapeutics Inc (Director · Jul 17, 2014 – Nov 9, 2015 · Past); Fate Therapeutics, Inc. (Director · Sep 30, 2013 – Oct 4, 2013 · Past); Kythera Biopharmaceuticals Inc (Director · Oct 10, 2012 – Aug 14, 2014 · Past); NeurogesX Inc (Director · May 1, 2007 – Jun 7, 2012 · Past); Adolor Corp (Director · May 18, 2006 – May 17, 2007 · Past)
Director · Jul 23, 2013 – Mar 3, 2017 · Past
Ian T. Clark
Other companies: Takeda Pharmaceutical Co. Ltd. (Director · Since at least Mar 18, 2026); BioMarin Pharmaceutical Inc. (Chair of the Board, · Since at least Aug 1, 2025); GoodRx Holdings, Inc. (Director · Since at least Jul 8, 2024); Kyverna Therapeutics, Inc. (Independent Director · Since at least Feb 7, 2024); Olema Pharmaceuticals, Inc. (Director · Since at least Aug 12, 2020); Guardant Health, Inc. (Director · Since at least Oct 3, 2018); Corvus Pharmaceuticals, Inc. (Director · Since at least Jan 3, 2017); Forty Seven Inc (Director · Jun 27, 2018 – Apr 7, 2020 · Past); Tectonic Therapeutic, Inc. (Director · Jun 20, 2018 – Jun 6, 2023 · Past); Kite Pharma Inc (Director · Jan 3, 2017 – Oct 3, 2017 · Past); Terravia Holdings Inc (Director · May 26, 2011 – May 22, 2017 · Past); Dendreon Corp (Director · Oct 7, 2009 – Aug 20, 2010 · Past); Genentech Inc (EVP-COMMERCIAL · Sep 20, 2006 – Mar 26, 2009 · Past)
Director · Dec 30, 2016 – May 20, 2022 · Past
John M. Maraganore
Other companies: City Therapeutics, Inc. (Executive Chair · Since at least Oct 19, 2026); Takeda Pharmaceutical Co. Ltd. (Director · Since at least Mar 18, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Jan 29, 2026); Rapport Therapeutics, Inc. (Venture Partner, ARCH Venture Partners and Atlas Ventures · Since at least Jun 6, 2024); Kymera Therapeutics, Inc. (Director · Since at least Jan 17, 2022); Beam Therapeutics Inc. (Board Member · Since at least Nov 5, 2021); Alnylam Pharmaceuticals, Inc. (Director · Since at least May 12, 2006); Instil Bio, Inc. (Director · Jun 11, 2025 – Nov 4, 2026 · Past); ProKidney Corp. (Director · Jul 11, 2022 – Jun 29, 2023 · Past); Bluebird bio Inc (Director · Jun 18, 2013 – Sep 14, 2017 · Past); Regulus Therapeutics Inc (Director · Oct 4, 2012 – Oct 10, 2012 · Past)
Director · Jul 23, 2013 – Dec 31, 2022 · Past
Douglas G Cole
Other companies: Foghorn Therapeutics Inc. (Director · Since at least Oct 22, 2020); Sana Biotechnology, Inc. (Director · Feb 3, 2021 – Jun 6, 2024 · Past); Sigilon Therapeutics Inc (Director · Dec 3, 2020 – Aug 11, 2023 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jun 1, 2023 · Past); Quanterix Corporation (Director · Dec 6, 2017 – Jan 2, 2019 · Past); Editas Medicine, Inc. (Director · Feb 2, 2016 – Aug 17, 2017 · Past); Receptos Inc (Director · May 8, 2013 – Jul 17, 2013 · Past); Tetraphase Pharmaceuticals Inc (Director · Mar 19, 2013 – Mar 25, 2013 · Past); AVEO Pharmaceuticals Inc (Director · Mar 11, 2010 – May 12, 2011 · Past)
Director · Jul 23, 2013 – Aug 10, 2016 · Past
Cynthia Smith
Other companies: Tvardi Therapeutics, Inc. (Board Member · Since at least Apr 15, 2025); Protara Therapeutics, Inc. (Director · Since at least Jan 29, 2021); Spero Therapeutics, Inc. (Director · Since at least Mar 19, 2019); Akebia Therapeutics, Inc. (Senior Vice President, Market Access and Commercial Development · Since at least Aug 28, 2018); Dicerna Pharmaceuticals Inc (Director · Aug 13, 2018 – Dec 28, 2021 · Past); Alpine Immune Sciences Inc (Director · Nov 1, 2016 – Nov 1, 2016 · Past); ZS Pharma Inc (Chief Commercial Officer · Jun 17, 2014 – Dec 17, 2015 · Past)
Independent Director · Since at least Aug 11, 2022
Jeffrey Capello
Other companies: Neogen Corporation (Director · Since at least Sep 2, 2022); Biogen Inc. (EVP & Chief Financial Officer · Dec 11, 2017 – Feb 12, 2020 · Past); Decoy Therapeutics Inc. (Director · Apr 1, 2015 – Jul 26, 2017 · Past); Tempest Therapeutics, Inc. (Director · Jun 11, 2012 – Jul 4, 2018 · Past); Boston Scientific Corporation (EVP & Chief Financial Officer · Jun 16, 2008 – Nov 27, 2013 · Past); Sirtris Pharmaceuticals Inc (Director · Jan 2, 2008 – Jan 2, 2008 · Past); Revvity, Inc. (SVP & CFO · Jan 31, 2006 – Jan 29, 2008 · Past)
Independent Director · Since at least Jun 13, 2023
Perry A Karsen
Other companies: LENZ Therapeutics, Inc. (Director · Jan 13, 2021 – Jul 19, 2023 · Past); Jiya Acquisition Corp (Director · Nov 18, 2020 – Nov 18, 2020 · Past); Jounce Therapeutics Inc (Director · Jan 26, 2017 – May 3, 2023 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – Dec 17, 2020 · Past); OncoMed Pharmaceuticals Inc (Director · Jan 4, 2016 – Apr 23, 2019 · Past); Voyager Therapeutics, Inc. (Director · Nov 10, 2015 – Jun 13, 2019 · Past); Celgene Corporation (see remarks · Feb 15, 2012 – Dec 31, 2015 · Past)
Director · Jul 23, 2013 – Jun 23, 2015 · Past
David Schenkein
Other companies: Regeneron Pharmaceuticals, Inc. (Director · Since at least Sep 8, 2023); Prime Medicine, Inc. (Board Member · Since at least Oct 19, 2022); Denali Therapeutics Inc. (Director · Since at least Dec 7, 2017); Foundation Medicine Inc (Director · Sep 24, 2013 – Jun 16, 2016 · Past); Bluebird bio Inc (Director · Jun 18, 2013 – Jun 18, 2020 · Past); Foghorn Therapeutics Inc. (General Partner, Co-leader, Agios · Until Apr 13, 2026 · Past)
Director · Jul 23, 2013 – Jun 20, 2024 · Past
Jacqualyn A. Fouse
Other companies: Madrigal Pharmaceuticals, Inc. (Director · Since at least Mar 10, 2025); Incyte Corporation (Director · Since at least Nov 14, 2017); Perrigo Company plc (Director · Nov 6, 2012 – May 4, 2016 · Past); Celgene Corporation (see remarks, Director · Sep 27, 2010 – Feb 14, 2017 · Past); Dick's Sporting Goods Inc (Director · Sep 15, 2010 – Mar 22, 2020 · Past); Bunge Limited (Chief Financial Officer · Jul 23, 2007 – Sep 2, 2010 · Past)
Director · Since at least Dec 3, 2017
Kevin P Starr
Other companies: MyoKardia Inc (Director · Oct 28, 2015 – Mar 7, 2018 · Past); Global Blood Therapeutics Inc (Director · Aug 11, 2015 – Aug 17, 2015 · Past); Sage Therapeutics Inc (Director · Jul 17, 2014 – Jun 15, 2023 · Past); Larimar Therapeutics, Inc. (Director · Jun 18, 2014 – Sep 24, 2015 · Past); Alnylam Pharmaceuticals, Inc. (Director · Jun 1, 2007 – Jun 2, 2017 · Past); Human Genome Sciences Inc (Director · May 3, 2007 – Jul 10, 2007 · Past)
Director · Jul 23, 2013 – Feb 19, 2015 · Past
All 40 people
PersonSeat
Paul J. Clancy
Other companies: Sionna Therapeutics, Inc. (Chair · Since at least Feb 6, 2025); Xilio Therapeutics, Inc. (Director · Since at least Oct 21, 2021); EXACT Sciences Corporation (Director · Since at least Mar 18, 2021); Incyte Corporation (Director · Since at least Jan 20, 2015); Alexion Pharmaceuticals Inc (EVP, Chief Financial Officer · Jul 10, 2017 – Jul 11, 2019 · Past); Biogen Inc. (Executive VP and CFO · Aug 13, 2007 – Apr 25, 2017 · Past)
Director · Sep 24, 2013 – Jun 21, 2022 · Past
Steve L. Hoerter
Other companies: MBX Biosciences, Inc. (Chairman, President and CEO, Director · Since at least Apr 7, 2025); C4 Therapeutics, Inc. (Director · Since at least Nov 19, 2024); ORIC Pharmaceuticals, Inc. (Board Member, Chairman and CEO of MBX Biosciences · Since at least Aug 13, 2021); Constellation Pharmaceuticals Inc (Director · Sep 4, 2018 – Jul 15, 2021 · Past); Deciphera Pharmaceuticals LLC (President and CEO, Director · May 17, 2018 – Jun 11, 2024 · Past); Clovis Oncology Inc (See Remarks · Nov 15, 2011 – Mar 5, 2015 · Past)
Chief Commercial Officer · Feb 16, 2016 – Mar 1, 2019 · Past
Brian Goff
Other companies: Intellia Therapeutics, Inc. (Independent Director · Since at least Jun 13, 2024); Alexion Pharmaceuticals Inc (EVP & Chief Commercial Officer · Jun 1, 2017 – Jul 21, 2021 · Past); Baxalta Inc (EVP and President, Hematology · Jun 30, 2015 – Jun 3, 2016 · Past); Idenix Pharmaceuticals Inc (Director · Mar 27, 2012 – Mar 27, 2012 · Past)
Chief Executive Officer · Since at least Aug 8, 2022
Jay Backstrom
Other companies: LAVA Therapeutics NV (Director · Since at least Jan 1, 2025); Disc Medicine, Inc. (Director · Dec 29, 2022 – Dec 29, 2022 · Past); Scholar Rock Holding Corporation (CHIEF EXECUTIVE OFFICER, Director · Sep 20, 2022 – Mar 10, 2025 · Past); Acceleron Pharma Inc (EVP, Research and Development · Dec 10, 2019 – Nov 19, 2021 · Past)
Independent Director · Since at least Jul 8, 2025
Maykin Ho
Other companies: Neumora Therapeutics, Inc. (Director · Since at least Sep 14, 2023); BioMarin Pharmaceutical Inc. (Director · Since at least Feb 17, 2021); Kyntra Bio, Inc. (Director · Since at least Dec 5, 2018); PAREXEL International Corp (Director · Aug 26, 2015 – Sep 29, 2017 · Past)
Independent Director · Since at least Jun 23, 2015
Andrew Hirsch
Other companies: C4 Therapeutics, Inc. (President and Chief Executive Officer, Director · Since at least Oct 1, 2020); Editas Medicine, Inc. (Board Member · Since at least May 30, 2017); BIND Therapeutics Inc (PRESIDENT & CEO, Director · Sep 19, 2013 – Jun 22, 2015 · Past)
Chief Financial Officer · Sep 19, 2016 – Apr 22, 2020 · Past
David Scadden
Other companies: Editas Medicine, Inc. (Director · Since at least Feb 5, 2019); Carisma Therapeutics, Inc. (Director · Jun 30, 2024 – Jul 1, 2024 · Past); Dianthus Therapeutics, Inc. (Director · Jun 20, 2018 – Jun 28, 2022 · Past)
Independent Director · Since at least May 27, 2017
Kaye I Foster-Cheek
Other companies: Prime Medicine, Inc. (Director · Since at least Oct 19, 2022); Onyx Pharmaceuticals Inc (SVP, Global Human Resources · Sep 30, 2010 – Oct 1, 2013 · Past); Johnson & Johnson (VP, Human Resources · Feb 13, 2006 – Dec 31, 2009 · Past)
Director · Since at least Dec 9, 2014
Adams Catherine Owen
Other companies: ACADIA Pharmaceuticals Inc. (Chief Executive Officer, Director · Since at least Sep 23, 2024); OptiNose (Director · Jul 29, 2020 – Jun 6, 2024 · Past)
Director · Since at least Jun 13, 2023
Jonathan Biller
Other companies: Vertex Pharmaceuticals Incorporated (EVP and Chief Legal Officer · Since at least Sep 19, 2022); Celgene Corporation (EVP AND GENERAL COUNSEL · Jul 3, 2018 – Nov 20, 2019 · Past)
Chief Financial Officer · Dec 3, 2019 – Mar 1, 2022 · Past
Bruce D. Car
Other companies: Biohaven Ltd. (Chief Innovation Officer · Since at least Sep 28, 2022)
Chief Scientific Officer · Jan 6, 2020 – Mar 1, 2022 · Past
Carman Alenson
Other companies: Prime Medicine, Inc. (See Remarks · Since at least Oct 19, 2022)
Principal Accounting Officer · Nov 7, 2016 – Jun 21, 2021 · Past
Cecilia Jones
Other companies: LogicBio Therapeutics Inc (Chief Financial Officer · Jan 11, 2021 – Mar 1, 2022 · Past)
Chief Financial Officer · Since at least Sep 26, 2022
Glenn Goddard
Other companies: Intellia Therapeutics, Inc. (EVP, Chief Financial Officer · Oct 29, 2018 – Mar 1, 2024 · Past)
Senior Vice President, Finance · Jul 23, 2013 – Feb 16, 2016 · Past
John Duncan Higgons
Other companies: Jounce Therapeutics Inc (Director · Jan 26, 2017 – Jun 24, 2022 · Past)
Chief Operating Officer · Jul 23, 2013 – Jan 4, 2016 · Past
Kaye Foster
Other companies: Prime Medicine, Inc. (Board Member · Since at least Nov 4, 2026)
Independent Director · Since at least Nov 5, 2026
Krishnan Viswanadhan
Other companies: CARGO Therapeutics, Inc. (Director · Since at least Nov 9, 2023)
Chief Strategy and Operations Officer · Since at least Mar 5, 2025
Rahul Ballal
Other companies: Enliven Therapeutics, Inc. (Member of the Board of Directors · Since at least Mar 11, 2020)
Independent Director · Since at least Aug 11, 2022
Sarah Gheuens
Other companies: Viridian Therapeutics, Inc. (Chief Medical Officer, Head of R&D, Agios Pharmaceuticals · Since at least Sep 21, 2023)
Chief Medical Officer, Head of R&D · Since at least Sep 1, 2021
Scott Biller
Other companies: Foghorn Therapeutics Inc. (Executive Venture Partner, Google Ventures (GV) · Since at least Oct 22, 2020)
Chief Scientific Officer · Jul 23, 2013 – Jun 11, 2019 · Past
Catherine OwenIndependent Director · Since at least Nov 5, 2026
Contacts:Investor ContactMorgan SanfordVice President, Investor Relations Agios · Since at least Mar 2, 2026
Darrin MilesChief Commercial Officer · Jan 16, 2021 – May 14, 2021 · Past
Ellen LoprestiChief People Officer · Since at least Nov 5, 2026
Jackie FouseIndependent Director · Since at least Nov 5, 2026
James William BurnsChief Legal Officer · Since at least Jan 1, 2022
Jim BurnsChief Legal Officer · Since at least Apr 6, 2026
Richa PoddarChief Commercial Officer · Dec 6, 2021 – Oct 15, 2022 · Past
Theodore James Washburn JrPrincipal Accounting Officer · Since at least Aug 1, 2021
Tsveta MilanovaChief Commercial Officer · Since at least Jan 3, 2023

Open People

Log in to ask 6ix AI your own questions about Agios Pharmaceuticals, Inc.